Pfizer’s Celebrex, Merck Sharp & Dohme’s Vioxx and Boehringer Ingelheim’s Mobic take the top three slots.
But MSD’s Arcoxia – which only launched in the UK in April last year – has surged into fourth spot ahead of Shire’s Lodine SR, awareness of which has fallen from 77 per cent last year (PRWeek, 3 October 2003) to just 67 per cent.
It is the second time that Pharma Focus has been able to compare data from the same therapeutic area since PRWeek began publishing the table last year.
Mobic has fallen from 27 per cent in October 2003 to 23 per cent in respect of the percentage of GPs more likely to prescribe the drug as a result of promotional messages; other brands’ percentages remained at similar levels.
Pfizer’s Bextra, which launched too late to be included in last October’s table, has achieved 41 per cent awareness among GPs, with 16 per cent of GPs more likely to prescribe the drug as a result of the brand’s promotional messages – a higher score than for the more-established Lodine SR product.
NOP World Health senior research executive Jude Ryall said: ‘None of the products profiled pose a threat to the dominant positions achieved by Celebrex and Vioxx.’
She added: ‘Shire and Boehringer Ingelheim would need to formulate aggressive marketing strategies to raise the profiles of Lodine SR and Mobic respectively if they are to present effective competition to the two market leaders.’
Two-hundred GPs were surveyed online by NOP World Health via GP Net.
NEXT MONTH: Drugs for high blood pressure